An exceptional response to immunotherapy with chemotherapy in metastatic lung cancer

Lung cancer is the leading cause of cancer death in men in Romania and more recently is a common cause of mortality among women. The main risk factor is smoking. The prognosis of patients diagnosed with advanced lung cancer is generally considered poor, with a median survival of 8-10 months and a 2-year survival of no more than 10%-20%. The use of checkpoint immunity inhibitors in many malignancies, including lung cancer, has revolutionized the field of oncology and improved the functions of the immune system in fighting cancer. However, only a few patients get clinically significant benefits, ranging from an improved quality of life to lasting clinical responses, including complete remissions that can last for many months even beyond the interruption of immunotherapy. Here, we describe the clinical course of a patient with metastatic lung cancer, who had an exceptional response to combination therapy immunotherapy- chemotherapy.

Abstract licence: CC BY

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.